1. Multiparametric phenotyping of compound effects on patient derived organoids
- Author
-
Betge, Johannes, Rindtorff, Niklas, Sauer, Jan, Rauscher, Benedikt, Dingert, Clara, Gaitantzi, Haristi, Herweck, Frank, Miersch, Thilo, Valentini, Erica, Hauber, Veronika, Gutting, Tobias, Frank, Larissa, Belle, Sebastian, Gaiser, Timo, Buchholz, Inga, Jesenofsky, Ralf, Härtel, Nicolai, Zhan, Tianzuo, Fischer, Bernd, Breitkopf-Heinlein, Katja, Burgermeister, Elke, Ebert, Matthias P., and Boutros, Michael
- Abstract
Patient derived organoids (PDOs) closely resemble individual tumor biology and allow testing of small molecules ex vivo . To systematically dissect compound effects on 3D organoids, we developed a high-throughput imaging and quantitative analysis approach. We generated PDOs from colorectal cancer patients, treated them with >500 small molecules and captured >3 million images by confocal microscopy. We developed the software framework SCOPE to measure compound induced re-organization of PDOs. We found diverse, but re-occurring phenotypes that clustered by compound mode-of-action. Complex phenotypes were not congruent with PDO viability and many were specific to subsets of PDO lines or were influenced by recurrent mutations. We further analyzed specific phenotypes induced by compound classes and found GSK3 inhibitors to disassemble PDOs via focal adhesion signaling or that MEK inhibition led to bloating of PDOs by enhancing of stemness. Finally, by viability classification, we show heterogeneous susceptibilities of PDOs to clinical anticancer drugs.
- Published
- 2019
- Full Text
- View/download PDF